The global stem cells market is estimated to reach $88.3 billion by 2014, growing at a CAGR of 14.8 % from 2009 to 2014, driven by the increasing demand of stem cell therapy in the field of regenerative medicine. The markets for stem cell products, technology and services are expected to grow at a CAGR of 13.9 %, 12.3 % and 16.1 % respectively. In addition to regenerative medicine, stem cells have applications in the field of drug discovery and development in cell based assays for ADME and toxicity studies. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market.

The recent reversal of 2001 ban on human embryonic stem cells research by US President Barack Obama has enabled immense market growth in US, inviting investments in this area. Meanwhile, Asian countries such as Singapore, China and Japan have developed robust infrastructure, taking advantage of the ban on human embryonic stem cells research due to religious and political issues in US and Europe. Increasing public support is pushing the market further.

Adult stem cells form the chief share of the market as they are the only cells presently that are marketable as a therapy. Moreover, availability of safety and efficacy data is also significant in making it a major profit making component in the market.  Animal and human embryonic stem cells are in clinical trials for their applications in chronic diseases.

Stem cell have vast potential in disease areas such as cardiovascular, neurological, diabetes, Parkinson’s and Alzheimer’s with various clinical trials underway in the mentioned focus areas. The use of stem cells as a drug discovery tool is a new development in this area which is driving the market with pharmaceutical giants such as Pfizer and Roche now adopting it. Market players are now focusing on new product and service development to enhance their commercial portfolios. Strategic collaborations among companies are also a common trend in the industry.

This analyst briefing focuses on the stem cells market over the period 2009-2014.The agenda for the briefing includes discussion on key high growth market, marking the growth trend in the product, technology, services and applications of stem cells. Furthermore, a briefing will be conducted on the competitive scenario and geographic opportunities for the same topic. It analyzes the major opportunities for the global stem cells market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions.

MarketsandMarkets, a research and consulting firm now onto publishing, is producing high level strategically analyzed 250 page reports about 120 a year. Worldwide, market research reports are primarily sold for numbers, market segmentation and competitive landscape, within the business leaders. MarketsandMarkets reports are equipped with more than 100+ market data summary tables, in-depth segmentation up to level 5 for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports of about 250 pages analyze about 200 patents, over 40 companies and micro markets which are collectively exhaustive but mutually exclusive. The analyst working with MarketsandMarkets come from the renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a database of hundred thousand of key industry participants and draw on our relationship with more than 900 market research companies globally. We, at MarketsandMarkets, are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our report, please visit our website (www.marketsandmarkets.com)

Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your successful registration.